Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Hematologic Oncology Update
00:00
Acalabrutinib‑venetoclax scheduling and ramp‑up
Rogers outlines the Amplify schedule (two months acalabrutinib then venetoclax) and flexibility for symptomatic patients.
Play episode from 25:44
Transcript
